Myomo, INC 10-Q quarterly reports

Myomo, Inc. announced its second quarter 2026 financial results, showcasing a 21% increase in revenue and a significant improvement in gross margins, though net losses persist.

Myomo Inc. reported a 3% increase in Q1 2026 revenue to $10.11 million, but net loss widened to $3.01 million, impacted by increased operating expenses and derivative liability revaluation.

Myomo, Inc. reported increased revenue for Q3 and YTD 2025, but also significantly wider net losses and higher cash burn, while securing $17.5 million in new committed debt capital.

Myomo, Inc. reported a significant increase in net loss for the second quarter and first half of 2025 despite substantial revenue growth, driven by higher operating expenses and a decline in gross margin.

Myomo Inc. reports a significant increase in first-quarter revenue, driven by growth in its direct billing channel and higher average selling prices, despite ongoing net losses.

Myomo Inc. saw a significant increase in product revenue and gross profit in the third quarter of 2024, driven by Medicare reimbursements, and anticipates achieving operating cash flow breakeven by the end of the year.

Myomo Inc. saw a significant increase in product revenue in the second quarter of 2024, primarily due to Medicare Part B reimbursements and higher average selling prices.

Myomo Inc. reports a net loss for Q1 2024, but highlights progress in Medicare reimbursement and plans for growth.